Rosiglitazone inhibits vascular K ATP channels and coronary vasodilation produced by isoprenaline

British Journal of Pharmacology

Volumn 164, Issue 8, 2011, Pages 2064-2072

  Yu, Lei ^a,b   Jin, Xin ^a   Yang, Yang ^a   Cui, Ningren ^a   Jiang, Chun ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

cardiovascular; heart; mouse; potassium channel; thiazolidinedione; type 2 diabetes mellitus; vascular tones

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; ISOPRENALINE; PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ARTERY TONE; ARTICLE; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; ISOLATED HEART; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHOLE CELL; WILD TYPE;

CELL LINE; CORONARY VESSELS; HUMANS; HYPOGLYCEMIC AGENTS; ISOPROTERENOL; PATCH-CLAMP TECHNIQUES; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 81855203418     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01539.x     Document Type: Article

References (51)

1. Abe M, Takiguchi Y, Ichimaru S, Kaji S, Tsuchiya K, Wada K, (2008). Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method. Eur J Pharmacol 589: 215-219.
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Ashcroft FM, (2006). From molecule to malady. Nature 440: 440-447.
4. Barnett AH, (2009). Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 5: 141-151.
5. Chang TJ, Chen WP, Yang C, Lu PH, Liang YC, Su MJ, et al,. (2009). Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats. Diabetologia 52: 1112-1121.
6. Chutkow WA, Pu J, Wheeler MT, Wada T, Makielski JC, Burant CF, et al,. (2002). Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. J Clin Invest 110: 203-208. (Pubitemid 34787357)
7. Coppack SW, Lant AF, McIntosh CS, Rodgers AV, (1990). Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 29: 673-684. (Pubitemid 20183666)
8. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, et al,. (2000). Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 28: 772-780. (Pubitemid 30470827)
9. Duan SZ, Usher MG, Mortensen RM, (2008). Peroxisome proliferator- activated receptor-gamma-mediated effects in the vasculature. Circ Res 102: 283-294. (Pubitemid 351271648)
10. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al,. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139.
11. Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M, (2001). Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 423: 1-7. (Pubitemid 32595721)
12. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al,. (2008). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559. (Pubitemid 351831356)
13. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al,. (2007). Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357: 28-38. (Pubitemid 47026732)
14. How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, et al,. (2007). Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 113: 211-220.
15. Irat AM, Aslamaci S, Karasu C, Ari N, (2006). Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones. J Pharm Pharmacol 58: 1647-1653. (Pubitemid 46051681)
16. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, et al,. (2009). PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 119: 110-124.
17. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH, (2010). Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. J Am Coll Cardiol 55: 1885-1894.
18. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A, (2002). Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51: 1507-1514. (Pubitemid 34826618)
19. Kilter H, Werner M, Roggia C, Reil JC, Schafers HJ, Kintscher U, et al,. (2009). The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes Obes Metab 11: 1060-1067.
20. Knock GA, Mishra SK, Aaronson PI, (1999). Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 368: 103-109. (Pubitemid 29106420)
21. Li H, Chai Q, Gutterman DD, Liu Y, (2003). Elevated glucose impairs cAMP-mediated dilation by reducing Kv channel activity in rat small coronary smooth muscle cells. Am J Physiol Heart Circ Physiol 285: H1213-H1219. (Pubitemid 37048179)
22. Lu L, Reiter MJ, Xu Y, Chicco A, Greyson CR, Schwartz GG, (2008a). Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia 51: 675-685.
23. Lu YL, Jimbu YM, Chen Y, Zhao JB, Ye TT, Yang H, (2008b). The effects of rosiglitazione on renal artery endothelium in diabetic rats. Exp Clin Endocrinol Diabetes 116: 537-540.
24. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N, (2008). Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 10: 1221-1238.
25. Miki T, Suzuki M, Shibasaki T, Uemura H, Sato T, Yamaguchi K, et al,. (2002). Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med 8: 466-472. (Pubitemid 34546748)
26. Mishra SK, Aaronson PI, (1999). Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K(+) current in rat aorta myocytes. Eur J Pharmacol 386: 121-125. (Pubitemid 30009631)
27. Nichols CG, (2006). KATP channels as molecular sensors of cellular metabolism. Nature 440: 470-476.
28. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471. (Pubitemid 46919772)
29. Orie NN, Thomas AM, Perrino BA, Tinker A, Clapp LH, (2009). Ca2+/calcineurin regulation of cloned vascular K ATP channels: crosstalk with the protein kinase A pathway. Br J Pharmacol 157: 554-564.
30. Potenza MA, Gagliardi S, De Benedictis L, Zigrino A, Tiravanti E, Colantuono G, et al,. (2009). Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am J Physiol Endocrinol Metab 297: E685-E694.
31. Psaty BM, Furberg CD, (2007). The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357: 67-69. (Pubitemid 47026739)
32. Quayle JM, Nelson MT, Standen NB, (1997). ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77: 1165-1232. (Pubitemid 27459582)
33. Savoia C, Ebrahimian T, Lemarie CA, Paradis P, Iglarz M, Amiri F, et al,. (2010). Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clin Sci (Lond) 118: 583-592.
34. Shi W, Cui N, Shi Y, Zhang X, Yang Y, Jiang C, (2007a). Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C. Am J Physiol Regul Integr Comp Physiol 293: R191-R199. (Pubitemid 47092177)
35. Shi Y, Wu Z, Cui N, Shi W, Yang Y, Zhang X, et al,. (2007b). PKA phosphorylation of SUR2B subunit underscores vascular KATP channel activation by beta-adrenergic receptors. Am J Physiol Regul Integr Comp Physiol 293: R1205-R1214. (Pubitemid 47358942)
36. Shi Y, Chen X, Wu Z, Shi W, Yang Y, Cui N, et al,. (2008a). cAMP-dependent protein kinase phosphorylation produces interdomain movement in SUR2B leading to activation of the vascular KATP channel. J Biol Chem 283: 7523-7530.
37. Shi Y, Cui N, Shi W, Jiang C, (2008b). A short motif in Kir6.1 consisting of four phosphorylation repeats underlies the vascular KATP channel inhibition by protein kinase C. J Biol Chem 283: 2488-2494.
38. Shi W, Cui N, Wu Z, Yang Y, Zhang S, Gai H, et al,. (2010). Lipopolysaccharides up-regulate Kir6.1/SUR2B channel expression and enhance vascular KATP channel activity via NF-kappaB-dependent signaling. J Biol Chem 285: 3021-3029.
39. Torres Tda S, Aguila MB, Mandarim-de-Lacerda CA, (2010). Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring. Pathol Res Pract 206: 642-646.
40. Vanasse A, Carpentier AC, Courteau J, Asghari S, (2009). Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diab Vasc Dis Res 6: 87-93.
41. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G, (1998). Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47: 810-814. (Pubitemid 28201812)
42. Wang X, Wu J, Li L, Chen F, Wang R, Jiang C, (2003). Hypercapnic acidosis activates KATP channels in vascular smooth muscles. Circ Res 92: 1225-1232. (Pubitemid 36723650)
43. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, et al,. (2006). Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317: 37-43.
44. Wang CX, Ding X, Noor R, Pegg C, He C, Shuaib A, (2009). Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 29: 1683-1694.
45. Wang Y, Lau WB, Gao E, Tao L, Yuan Y, Li R, et al,. (2010). Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 298: E663-E670.
46. Wong H, Ozalp Y, Lainesse A, Alpan RS, (2004). In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. Arzneimittelforschung 54: 618-624. (Pubitemid 39278905)
47. Yang Y, Shi Y, Guo S, Zhang S, Cui N, Shi W, et al,. (2008). PKA-dependent activation of the vascular smooth muscle isoform of KATP channels by vasoactive intestinal polypeptide and its effect on relaxation of the mesenteric resistance artery. Biochim Biophys Acta 1778: 88-96.
48. Yang Y, Shi W, Cui N, Wu Z, Jiang C, (2010). Oxidative stress inhibits vascular K(ATP) channels by S-glutathionylation. J Biol Chem 285: 38641-38648.
49. Yang Y, Shi W, Chen X, Cui N, Konduru AS, Shi Y, et al,. (2011). Molecular basis and structural insight of vascular KATP channel gating by S-glutathionylation. J Biol Chem 286: 9298-9307.
50. Yu J, Zhang Z, Li Z, Feng X, He L, Liu S, et al,. (2010). Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 38: 86-94.
51. Zinn A, Felson S, Fisher E, Schwartzbard A, (2008). Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 31: 397-403.